Targeting oncogene dependence and resistance.

Abstract excerpt

Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Enzyme Inhibitors
• Share to Fusion Proteins, bcr-abl